InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,481.45
(
0.31%
)
US TECH 100
19,110.40
(
-0.50%
)
Dow Jones
39,492.42
(
0.87%
)
Brent Oil
85.24
(
1.45%
)
Bitcoin
60,740.60
(
-3.83%
)

Replies to post #123390 on Biotech Values

Replies to #123390 on Biotech Values

genisi

07/15/11 6:13 AM

#123394 RE: DewDiligence #123390

The FDA rejected the brand name Omnitarg for Pertuzumab because its phonetic sound implies the drug has some unique effectiveness i.e. all/many targets, and it's misleading.

RockRat

07/15/11 9:40 AM

#123407 RE: DewDiligence #123390

"Why did the FDA reject the brand name, Omnitarg for Pertuzumab?"

It was rejected because it sounded similar to PFE's Mylotarg and the FDA was afraid of confusion.

Regards, RockRat